Preview

Бюллетень сибирской медицины

Расширенный поиск

Аллельные варианты генов человека, затрагивающие внутриклеточный жизненный цикл ВИЧ и регулирующие иммунный ответ на ВИЧ-инфекцию

https://doi.org/10.20538/1682-0363-2019-1-119-130

Полный текст:

Аннотация

В обзоре рассмотрены генетические факторы хозяина, влияющие на внутриклеточную часть жизненного цикла вируса иммунодефицита человека (ВИЧ), а также регулирующие ВИЧ-специфический иммунный ответ. К ним относятся гены, которые кодируют белки, обеспечивающие репликацию вируса и формирование новых вирионов; гены, кодирующие противовирусные защитные белки; гены HLA и ряд других. Варианты этих генов и их сочетания вносят вклад в устойчивость или чувствительность индивидуума к ВИЧ-инфекции, влияют на патогенез заболевания, а также связаны с эффективностью антиретровирусной терапии.

Об авторах

Р. М. Хаитов
Институт иммунологии
Россия

Хаитов Рахим Мусаевич, доктор медицинских наук, профессор, академик РАН, научный руководитель Института иммунологии

115478, г. Москва, Каширское шоссе, 24



Л. П. Алексеев
Институт иммунологии
Россия

Алексеев Леонид Петрович, доктор медицинских наук, профессор, член-корреспондент РАН, заведующий отделом, Институт иммунологии

115478, г. Москва, Каширское шоссе, 24



Г. О. Гудима
Институт иммунологии
Россия

Гудима Георгий Олегович, доктор биологических наук, заведующий лабораторией

115478, г. Москва, Каширское шоссе, 24



И. А. Кофиади
Институт иммунологии
Россия

Кофиади Илья Андреевич, доктор биологических наук, заведующий лабораторией

115478, г. Москва, Каширское шоссе, 24



Список литературы

1. Fellay J., Ge D., Shianna K., Colombo S., Ledergerber B., Cirulli E., Urban T., Zhang K., Gumbs C., Smith J., Castagna A., Cozzi-Lepri A., De Luca A., Easterbrook P., Gьnthard H., Mallal S., Mussini C., Dalmau J., Martinez-Picado J., Miro J., Obel N., Wolinsky S., Martinson J., Detels R., Margolick J., Jacobson L., Descombes P., Antonarakis S., Beckmann J., O’Brien S., Letvin N., McMichael A., Haynes B., Carrington M., Feng S., Telenti A., Goldstein D. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 2009; 5 (12): e1000791. DOI: 10.1371/journal.pgen.1000791.

2. Konig R., Zhou Y., Elleder D., Diamond T., Bonamy G., Irelan J., Chiang C., Tu B., De Jesus P., Lilley C., Seidel S., Opaluch A., Caldwell J., Weitzman M., Kuhen K., Bandyopadhay S., Ideker T., Orth A., Miraglia L., Bushman F., Young J., Chanda S. Global analysis of hostpathogen interactions that regulate early-stage HIV-1 replication. Cell. 2008; 135 (1): 49–60. DOI: 10.1016/j.cell.2008.07.032.

3. McLaren P., Carrington M. The impact of host genetic variation on infection with HIV-1. Nat. Immunol. 2015; 16 (6): 577–583. DOI: 10.1038/ni.3147.

4. Хаитов Р.М. СПИД. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2018: 496.

5. Bashirova A., Bleiber G., Qi Y., Hutcheson H., Yamashita T., Johnson R., Cheng J., Alter G., Goedert J., Buchbinder S., Hoots K., Vlahov D., May M., Maldarelli F., Jacobson L., O’Brien S., Telenti A., Carrington M. Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J. Virol. 2006; 80 (14): 6757–6763. DOI: 10.1128/JVI.00094-06.

6. Liu C., Perilla J., Ning J., Lu M., Hou G., Ramalho R., Himes B., Zhao G., Bedwell G., Byeon I., Ahn J., Gronenborn A., Prevelige P., Rousso I., Aiken C., Polenova T., Schulten K., Zhang P. Cyclophilin A stabilizes the HIV-1 capsid through a novel non-canonical binding site. Nat. Commun. 2016; 7: 10714. DOI: 10.1038/ncomms10714.

7. Rits M., van Dort K., Kootstra N. Polymorphisms in the regulatory region of the Cyclophilin A gene influence the susceptibility for HIV-1 infection. PLoS One. 2008; 3 (12): e3975. DOI: 10.1371/journal.pone.0003975.

8. Madlala P., Singh R., An P., Werner L., Mlisana K., Abdool Karim S., Winkler C., Ndung’u T. Association of polymorphisms in the regulatory region of the cyclophilin A gene (PPIA) with gene expression and HIV/AIDS disease progression. J. Acquir. Immune Defic. Syndr. 2016; 72 (5): 465–473. DOI: 10.1097/QAI.0000000000001028.

9. Fribourgh J., Nguyen H., Wolfe L., Dewitt D., Zhang W., Yu X., Rhoades E., Xiong Y. Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase. J. Virol. 2014; 88 (6): 3309–3319. DOI: 10.1128/JVI.03824-13.

10. Evans S., Schön A., Gao Q., Han X., Zhou X., Freire E., Yu X. HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3. Retrovirology. 2014; 11: 4–14. DOI: 10.1186/1742-4690-11-4.

11. An P., Duggal P., Wang L., O’Brien S., Donfield S., Goedert J., Phair J., Buchbinder S., Kirk G., Winkler C. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet. 2007; 3 (1): e19. DOI: 10.1371/journal.pgen.0030019.

12. Towers G. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology. 2007; 4: 40. DOI: 10.1186/1742-4690-4-40.

13. Yamashita M., Emerman M. Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells. J. Virol. 2009; 83 (19): 9835–9843. DOI: 10.1128/JVI.01084-09.

14. van Manen D., Rits M., Beugeling C., van Dort K., Schuitemaker H., Kootstra N. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog. 2008; 4 (2): e18. DOI: 10.1371/journal.ppat.0040018.

15. Jaguva Vasudevan A., Smits S., Höppner A., Häussinger D., Koenig B., Münk C. Structural features of antiviral DNA cytidine deaminases. Biol Chem. 2013; 394 (11): 1357–1370. DOI: 10.1515/hsz-2013-0165.

16. Valcke H., Bernard N., Bruneau J., Alary M., Tsoukas C., Roger M. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS. 2006; 20 (15): 1984–1986. DOI: 10.1097/01.aids.0000247124.35129.e1.

17. An P., Johnson R., Phair J., Kirk G., Yu X., Donfield S., Buchbinder S., Goedert J., Winkler C. APOBEC3B Deletion and Risk of HIV-1 Acquisition. J. Infect. Dis. 2009; 200 (7): 1054–1058. DOI: 10.1086/605644.

18. Naruse T., Sakurai D., Ohtani H., Sharma G., Sharma S., Vajpayee M., Mehra N., Kaur G., Kimura A. APOBEC3H polymorphisms and susceptibility to HIV-1 infection in an Indian population. J. Hum. Genet. 2016; 61 (3): 263–265. DOI: 10.1038/jhg.2015.136.

19. An P., Penugonda S., Thorball C., Bartha I., Goedert J., Donfield S., Buchbinder S., Binns-Roemer E., Kirk G., Zhang W., Fellay J., Yu X., Winkler C. Role of APOBEC3F gene variation in HIV-1 disease Progression and Pneumocystis pneumonia. PLoS Genet. 2016; 12 (3): e1005921. DOI: 10.1371/journal.pgen.1005921.

20. Altfeld M., Kalife E.T., Qi Y., Streeck H., Lichterfeld M., Johnston M., Burgett N., Swartz M., Yang A., Alter G., Yu X., Meier A., Rockstroh J., Allen T., Jessen H., Rosenberg E., Carrington M., Walker B. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med. 2006; 3 (10): e403. DOI: 10.1371/journal.pmed.0030403.

21. Masemola A., Mashishi T., Khoury G., Mohube P., Mokgotho P., Vardas E., Colvin M., Zijenah L., Katzenstein D., Musonda R., Allen S., Kumwenda N., Taha T., Gray G., McIntyre J., Karim S.A., Sheppard H.W., Gray C.M. HIVNET 028 Study Team. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J. Virol. 2004; 78 (7): 3233–3243. DOI: 10.1128/JVI.78.7.3233-3243.2004.

22. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., Rathnavalu P., Moore C., Pfafferott K.J., Hilton L., Zimbwa P., Moore S., Allen T., Brander C., Addo M., Altfeld M., James I., Mallal S., Bunce M., Barber L.D., Szinger J., Day C., Klenerman P., Mullins J., Korber B., Coovadia H.M., Walker B.D., Goulder P.J. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004; 432 (7018): 769–775. DOI: 10.1038/nature03113.

23. Gao X., Bashirova A., Iversen A., Phair J., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Altfeld M., O’Brien S., Carrington M. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat. Med. 2005; 11 (12): 1290–1292. DOI: 10.1038/nm1333.

24. Gillespie G., Kaul R., Dong T., Yang H., Rostron T., Bwayo J., Kiama P., Peto T., Plummer F., McMichael A., Rowland-Jones S. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS. 2002; 16 (7): 961–972. DOI: 10.1097/00002030-200205030-00002.

25. Miura T., Brockman M.A., Schneidewind A., Lobritz M., Pereyra F., Rathod A., Block B.L., Brumme Z.L., Brumme C.J., Baker B., Rothchild A.C., Li B., Trocha A., Cutrell E., Frahm N., Brander C., Toth I., Arts E.J., Allen T.M., Walker B.D. HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition. J. Virol. 2009; 83 (6): 2743–2755. DOI: 10.1128/JVI.02265-08.

26. Kaur G., Mehra N. Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. Tissue Antigens. 2009; 74 (5): 373–385. DOI: 10.1111/j.1399-0039.2009.01337.x.

27. Bailey J., Williams T., Siliciano R., Blankson J. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 2006; 203 (5): 1357–1369. DOI: 10.1084/jem.20052319.

28. Van Manen D., van Wout A., Schuitemaker H. Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics. Retrovirology. 2012; 9: 70. DOI: 10.1186/1742-4690-9-70.

29. Hewitt R. Abacavir Hypersensitivity Reaction. Clin. Infect. Dis. 2002; 34 (8): 1137–1142. DOI: 10.1086/339751.

30. Colombo S., Rauch A., Rotger M., Fellay J., Martinez R., Fux C., Thurnheer C., Günthard H.F., Goldstein D.B., Furrer H., Telenti A. Swiss HIV Cohort Study. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 2008; 198 (6): 864–867. DOI: 10.1086/591184.

31. Chessman D., Kostenko L., Lethborg T., Purcell A.W., Williamson N., Chen Z., Kjer-Nielsen L., Mifsud N., Tait B., Holdsworth R., Almeida C., Nolan D., Macdonald W., Archbold J., Kellerher A., Marriott D., Mallal S., Bharadwaj M., Rossjohn J., McCluskey J. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity. 2008; 28 (6): 822–832. DOI: 10.1016/j.immuni.2008.04.020.

32. Mallal S., Nolan D., Witt C., Masel G., Martin A., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., Christiansen F. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; 359 (9308): 727–732. DOI: 10.1016/S0140-6736(02)07873-X.

33. Martin A., Nolan D., Gaudieri S., Almeida C.A., Nolan R., James I., Carvalho F., Phillips E., Christiansen F., Purcell A., McCluskey J., Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. USA. 2004; 101 (12): 4180–4185. DOI: 10.1073/pnas.0307067101.

34. Rauch A., Nolan D., Thurnheer C., Fux C., Cavassini M., Chave J., Opravil M., Phillips E., Mallal S., Furrer H.; Swiss HIV Cohort Study. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir. Ther. 2008; 13 (8): 1019–1028. DOI: 10.1086/504874.

35. Mahungu T., Johnson M., Owen A., Back D. The impact of pharmacogenetics on HIV therapy. Int. J. STD AIDS. 2009; 20 (3): 145–151. DOI: 10.1258/ijsa.2008.008369.

36. Schneidewind A., Brockman M., Yang R., Adam R., Li B., Le Gall S., Rinaldo C., Craggs S., Allgaier R., Power K., Kuntzen T., Tung C., LaBute M., Mueller S., Harrer T., McMichael A., Goulder P., Aiken C., Brander C., Kelleher A., Allen T. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 2007; 81 (22): 12382–12393. DOI: 10.1128/JVI.01543-07.

37. Cornelissen M., Hoogland F., Back N., Jurriaans S., Zorgdrager F., Bakker M., Brinkman K., Prins M., van der Kuyl A. Multiple transmissions of a stable human leucocyte antigen-B27 cytotoxic T-cell-escape strain of HIV- 1 in The Netherlands. AIDS. 2009; 23 (12): 1495–1500. DOI: 10.1097/QAD.0b013e32832d9267.

38. Stephens H. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol. 2005; 26 (1): 41–47. DOI: 10.1016/j.it.2004.11.001.

39. Lajoie J., Hargrove J., Zijenah L., Humphrey J., Ward B., Roger M. Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J. Infect. Dis. 2006; 193 (2): 298–301. DOI: 10.1086/498877.

40. McDonald K., Fowke K., Kimani J., Dunand V., Nagelkerke N., Ball T., Oyugi J., Njagi E., Gaur L., Brunham R., Wade J., Luscher M., Krausa P., Rowland-Jones S., Ngugi E., Bwayo J., Plummer F. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 2000; 181 (5): 1581–1589. DOI: 10.1086/315472.

41. Liu C., Carrington M., Kaslow R., Gao X., Rinaldo C., Jacobson L., Margolick J., Phair J., O’Brien S., Detels R. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 2003; 187 (9): 1404–1410. DOI: 10.1086/374394.

42. Flores-Villanueva P., Hendel H., Caillat-Zucman S., Rappaport J., Burgos-Tiburcio A., Bertin-Maghit S., Ruiz-Morales J., Teran M., Rodriguez-Tafur J., Zagury J. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J. Immunol. 2003; 170 (4): 1925–1929. DOI: 10.4049/jimmunol.170.4.1925.

43. Singh P., Kaur G., Sharma G., Mehra N. Immunogenetic basis of HIV-1 infection, transmission and disease progression. Vaccine. 2008; 26 (24): 2966–2980. DOI: 10.1016/j.vaccine.2008.01.012.

44. Adnan S., Balamurugan A., Trocha A., Bennett M., Ng H., Ali A., Brander C., Yang O. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood. 2006; 108 (10): 3414–3419. DOI: 10.1182/blood-2006-06-030668.

45. Trachtenberg E., Korber B., Sollars C., Kepler T., Hraber P., Hayes E., Funkhouser R., Fugate M., Theiler J., Hsu Y., Kunstman K., Wu S., Phair J., Erlich H., Wolinsky S. Advantage of rare HLA supertype in HIV disease progression. Nat. Med. 2003; 9 (7): 928–935. DOI: 10.1038/nm893.

46. HIV molecular immunology database. 2016. http://www.hiv.lanl.gov/content/immunology/.

47. Lacap P., Huntington J., Luo M., Nagelkerke N., Bielawny T., Kimani J., Wachihi C., Ngugi E., Plummer F. Associations of human leukocyte antigen DRB with resistance or susceptibility to HIV-1 infection in the Pumwani Sex Worker Cohort. AIDS. 2008; 22 (9): 1029–1038. DOI: 10.1097/QAD.0b013e3282ffb3db.

48. An P., Winkler C. Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet. 2010; 26 (3): 119–131. DOI: 10.1016/j.tig.2010.01.002.

49. Malhotra U., Holte S., Dutta S., Berrey M., Delpit E., Koelle D., Sette A., Corey L., McElrath M. Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J. Clin. Invest. 2001; 107 (4): 505–517. DOI: 10.1172/JCI11275.

50. Hardie R., Luo M., Bruneau B., Knight E., Nagelkerke N., Kimani J., Wachihi C., Ngugi E., Plummer F. Human leukocyte antigen-DQ alleles and haplotypes and their associations with resistance and susceptibility to HIV-1 infection. AIDS. 2008; 22 (7): 807–816. DOI: 10.1097/QAD.0b013e3282f51b71.

51. Carrington M., Martin M., van Bergen J. KIR-HLA intercourse in HIV disease. Trends Microbiol. 2008; 16 (12): 620–627. DOI: 10.1016/j.tim.2008.09.002

52. Boyton R., Altmann D. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin. Exp. Immunol. 2007; 149 (1): 1–8. DOI: 10.1111/j.1365-2249.2007.03424.x.

53. Jennes W., Verheyden S., Demanet C., Adjé-Touré C., Vuylsteke B., Nkengasong J., Kestens L. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J. Immunol. 2006; 177 (10): 6588– 6592. DOI: 10.4049/jimmunol.177.10.6588.

54. Qi Y., Martin M., Gao X., Jacobson L., Goedert J., Buchbinder S., Kirk G., O’Brien S., Trowsdale J., Carrington M. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2006; 2 (8): e79. DOI: 10.1371/journal.ppat.0020079.

55. Long B., Ndhlovu L., Oksenberg J., Lanier L., Hecht F., Nixon D., Barbour J. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J. Virol. 2008; 82 (10): 4785–4792. DOI: 10.1128/JVI.02449-07.

56. Alter G., Martin M., Teigen N., Carr W., Suscovich T., Schneidewind A., Streeck H., Waring M., Meier A., Brander C., Lifson J., Allen T., Carrington M., Altfeld M. Differential natural killer cell mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 2007; 204 (12): 3027–3036. DOI: 10.1084/jem.20070695.

57. Boulet S., Kleyman M., Kim J., Kamya P., Sharafi S., Simic N., Bruneau J., Routy J., Tsoukas C., Bernard N. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS. 2008; 22 (12): 1487–1491. DOI: 10.1097/QAD.0b013e3282ffde7e.

58. Habegger de Sorrentino A., Sinchi J.L., Marinic K., Lуpez R., Illiovich E. Kir-HLA-A and B alleles of the Bw4 epitope against HIV infection in discordant heterosexual couples in Chaco Argentina. Immunology. 2013; 140 (2): 273–279. DOI: 10.1111/imm.12137.

59. Lin Y., Lan Y., Hung C., Lin T., Huang S., Liao C., Lin C., Lai C., Tien N., Liu X., Ho M., Chien W., Chen J., Wang J., Tsai F. Variants in ZNRD1 gene predict HIV-1/AIDS disease progression in a Han Chinese population in Taiwan. PLoS One. 2013; 8 (7): e67572. DOI: 10.1371/journal.pone.0067572.

60. Ballana E., Senserrich J., Pauls E., Faner R., Mercader J. ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression. Clin. Infect. Dis. 2010; 50 (7): 1022–1032. DOI: 10.1086/651114.


Для цитирования:


Хаитов Р.М., Алексеев Л.П., Гудима Г.О., Кофиади И.А. Аллельные варианты генов человека, затрагивающие внутриклеточный жизненный цикл ВИЧ и регулирующие иммунный ответ на ВИЧ-инфекцию. Бюллетень сибирской медицины. 2019;18(1):119-130. https://doi.org/10.20538/1682-0363-2019-1-119-130

For citation:


Khaitov R.M., Alexeev L.P., Gudima G.O., Kofiadi I.A. Allelic variants of human genes affecting HIV intracellular life cycle and regulating immune response to HIV infection. Bulletin of Siberian Medicine. 2019;18(1):119-130. (In Russ.) https://doi.org/10.20538/1682-0363-2019-1-119-130

Просмотров: 51


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-0363 (Print)
ISSN 1819-3684 (Online)